 Patients admitted with Diabetic Ketoacidosis DKA to Hennepin County Medical Center HCMC who have a prior episode of DKA within 2 years will be offered enrollment in a prospective, randomized unblinded trial to determine whether long acting insulin degludec will reduce the rate of recurrent DKA and improve compliance over the period of 1 year when compared with the control group who will stay on their pre-study long acting insulin glargine or detemir. 